Nemolizumab

奈莫利珠单抗

Report date: 2026/05/28 20:00:21
First In Class

Base Information

Drug NameNemolizumab
Drug Alias Name奈莫利组单抗nemolizumabumNemolizumab-iltoMitchgaNemluvio +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-31 receptor subunit alpha antagonists
TargetsInterleukin-31 receptor subunit alpha
Therapy Area/IndicationsPrurigo NodularisPruritusPrurigo +[5] 
Global Approved IndicationsPruritusPrurigoDermatitis, Atopic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/03/28
Country/TerritoryCzechiaBelgiumBulgaria +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGalderma SaChugai Pharmaceutical Co LtdGalderma R&D +[6] 
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisPruritusPrurigo +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG